Pregnancy and Inflammatory Bowel Disease

Medical Clinics of North America

Volumn 94, Issue 1, 2010, Pages 53-73

  Mahadevan, Uma ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn disease; Inflammatory bowel disease; Infliximab; Pregnancy; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; AMINOSALICYLIC ACID DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; FISH OIL; FOLIC ACID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEVOFLOXACIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NORFLOXACIN; OLSALAZINE; PREDNISOLONE; PREDNISONE; RIFAXIMIN; RISEDRONIC ACID; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; UNINDEXED DRUG;

DRUG SAFETY; ENTERITIS; FEMALE FERTILITY; HUMAN; LACTATION; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW;

EID: 70450181229     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2009.08.018     Document Type: Review

References (134)

1. Andres P.G., and Friedman L.S. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 28 2 (1999) 255-281 vii
2. Orholm M., Fonager K., and Sorensen H.T. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol 94 11 (1999) 3236-3238
3. Orholm M., Munkholm P., Langholz E., et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 324 2 (1991) 84-88
4. Yang H., McElree C., Roth M.P., et al. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 34 4 (1993) 517-524
5. Bennett R.A., Rubin P.H., and Present D.H. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 100 6 (1991) 1638-1643
6. Klement E., and Reif S. Breastfeeding and risk of inflammatory bowel disease. Am J Clin Nutr 82 2 (2005) 486
7. Fielding J.F. Pregnancy and inflammatory bowel disease. Ir J Med Sci 151 6 (1982) 194-202
8. Mayberry J.F., and Weterman I.T. European survey of fertility and pregnancy in women with Crohn's disease: a case control study by European collaborative group. Gut 27 7 (1986) 821-825
9. Francella A., Dyan A., Bodian C., et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 124 1 (2003) 9-17
10. Hudson M., Flett G., Sinclair T.S., et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 58 2 (1997) 229-237
11. Baird D.D., Narendranathan M., and Sandler R.S. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology 99 4 (1990) 987-994
12. Willoughby C.P., and Truelove S.C. Ulcerative colitis and pregnancy. Gut 21 6 (1980) 469-474
13. Ording Olsen K., Juul S., Berndtsson I., et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 122 1 (2002) 15-19
14. Wikland M., Jansson I., Asztely M., et al. Gynaecological problems related to anatomical changes after conventional proctocolectomy and ileostomy. Int J Colorectal Dis 5 1 (1990) 49-52
15. Olsen K.O., Juul S., Bulow S., et al. Female fecundity before and after operation for familial adenomatous polyposis. Br J Surg 90 2 (2003) 227-231
16. Waljee A., Waljee J., Morris A.M., et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 55 11 (2006) 1575-1580
17. Cornish J.A., Tan E., Teare J., et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum 50 8 (2007) 1128-1138
18. Timmer A., Bauer A., Dignass A., et al. Sexual function in persons with inflammatory bowel disease: a survey with matched controls. Clin Gastroenterol Hepatol 5 1 (2007) 87-94
19. Van Horn C., and Barrett P. Pregnancy, delivery, and postpartum experiences of fifty-four women with ostomies. J Wound Ostomy Continence Nurs 24 3 (1997) 151-162
20. Kane S.V., Khatibi B., and Reddy D. Use of immunosuppressants results in higher incidence of abnormal PAP smears in women with inflammatory bowel disease. [abstract]. Gastroenterology 130 4 Suppl 2 (2006) A2
21. Venkatesan T.B.D., Ferrer V., Weber L., et al. Abnormal PAP smear, cervical dysplasia and immunomodulator therapy in women with inflammatory bowel disease. [abstract]. Gastroenterology 130 4 Suppl 2 (2006) A3
22. Singh H., Demers A.A., Nugent Z., et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 136 2 (2009) 451-458
23. Lees C.W., Critchley J., Chee N., et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis (2009) [Epub ahead of print]
24. Fonager K., Sorensen H.T., Olsen J., et al. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 93 12 (1998) 2426-2430
25. Kornfeld D., Cnattingius S., and Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease-a population-based cohort study. Am J Obstet Gynecol 177 4 (1997) 942-946
26. Norgard B., Fonager K., Sorensen H.T., et al. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am J Gastroenterol 95 11 (2000) 3165-3170
27. Dominitz J.A., Young J.C., and Boyko E.J. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol 97 3 (2002) 641-648
28. Norgard B., Puho E., Pedersen L., et al. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. Am J Gastroenterol 98 9 (2003) 2006-2010
29. Mahadevan U., Sandborn W.J., Li D.K., et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 133 4 (2007) 1106-1112
30. Cornish J., Tan E., Teare J., et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56 6 (2007) 830-837
31. Larzilliere I., and Beau P. Chronic inflammatory bowel disease and pregnancy. Case control study. Gastroenterol Clin Biol 22 12 (1998) 1056-1060 [in French]
32. Nielsen O.H., Andreasson B., Bondesen S., et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol 18 6 (1983) 735-742
33. Nielsen O.H., Andreasson B., Bondesen S., et al. Pregnancy in Crohn's disease. Scand J Gastroenterol 19 6 (1984) 724-732
34. Mogadam M., Korelitz B.I., Ahmed S.W., et al. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol 75 4 (1981) 265-269
35. Morales M., Berney T., Jenny A., et al. Crohn's disease as a risk factor for the outcome of pregnancy. Hepatogastroenterology 47 36 (2000) 1595-1598
36. Kane S., and Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol 100 1 (2005) 102-105
37. Agret F., Cosnes J., Hassani Z., et al. Impact of pregnancy on the clinical activity of Crohn's disease. Aliment Pharmacol Ther 21 5 (2005) 509-513
38. Castiglione F., Pignata S., Morace F., et al. Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. Ital J Gastroenterol 28 4 (1996) 199-204
39. Riis L., Vind I., Politi P., et al. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol 101 7 (2006) 1539-1545
40. Nelson J.L., Hughes K.A., Smith A.G., et al. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med 329 7 (1993) 466-471
41. Kane S., Kisiel J., Shih L., et al. HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. Am J Gastroenterol 99 8 (2004) 1523-1526
42. Bush M.C., Patel S., Lapinski R.H., et al. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 15 4 (2004) 237-241
43. Fedorkow D.M., Persaud D., and Nimrod C.A. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol 160 4 (1989) 998-1001
44. Moser M.A., Okun N.B., Mayes D.C., et al. Crohn's disease, pregnancy, and birth weight. Am J Gastroenterol 95 4 (2000) 1021-1026
45. Norgard B., Hundborg H.H., Jacobsen B.A., et al. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish Cohort Study. Am J Gastroenterol 102 9 (2007) 1947-1954
46. Ilnyckyji A., Blanchard J.F., Rawsthorne P., et al. Perianal Crohn's disease and pregnancy: role of the mode of delivery. Am J Gastroenterol 94 11 (1999) 3274-3278
47. Brandt L.J., Estabrook S.G., and Reinus J.F. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women with Crohn's disease. Am J Gastroenterol 90 11 (1995) 1918-1922
48. Hahnloser D., Pemberton J.H., Wolff B.G., et al. Pregnancy and delivery before and after ileal pouch-anal anastomosis for inflammatory bowel disease: immediate and long-term consequences and outcomes. Dis Colon Rectum 47 7 (2004) 1127-1135
49. Craxi A., and Pagliarello F. Possible embryotoxicity of sulfasalazine. Arch Intern Med 140 12 (1980) 1674
50. Hoo J.J., Hadro T.A., and Von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med 318 17 (1988) 1128
51. Newman N.M., and Correy J.F. Possible teratogenicity of sulphasalazine. Med J Aust 1 11 (1983) 528-529
52. Mogadam M., Dobbins III W.O., Korelitz B.I., et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 80 1 (1981) 72-76
53. Norgard B., Czeizel A.E., Rockenbauer M., et al. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 15 4 (2001) 483-486
54. Esbjorner E., Jarnerot G., and Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 76 1 (1987) 137-142
55. Habal F.M., Hui G., and Greenberg G.R. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 105 4 (1993) 1057-1060
56. Marteau P., Tennenbaum R., Elefant E., et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 12 11 (1998) 1101-1108
57. Trallori G., d'Albasio G., Bardazzi G., et al. 5-Aminosalicylic acid in pregnancy: clinical report. Ital J Gastroenterol 26 2 (1994) 75-78
58. Diav-Citrin O., Park Y.H., Veerasuntharam G., et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 114 1 (1998) 23-28
59. Norgard B., Fonager K., Pedersen L., et al. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut 52 2 (2003) 243-247
60. Nelis G.F. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet 1 8634 (1989) 383
61. Burtin P., Taddio A., Ariburnu O., et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 172 2 Pt 1 (1995) 525-529
62. Caro-Paton T., Carvajal A., Martin de Diego I., et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 44 2 (1997) 179-182
63. Piper J.M., Mitchel E.F., and Ray W.A. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 82 3 (1993) 348-352
64. Sorensen H.T., Larsen H., Jensen E.S., et al. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J Antimicrob Chemother 44 6 (1999) 854-856
65. Diav-Citrin O., Shechtman S., Gotteiner T., et al. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 63 5 (2001) 186-192
66. Czeizel A.E., and Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 105 3 (1998) 322-327
67. American Academy of Pediatrics. Committee on Drugs. Naloxone use in newborns. Pediatrics 65 3 (1980) 667-669
68. Niebyl J.R. Antibiotics and other anti-infective agents in pregnancy and lactation. Am J Perinatol 20 8 (2003) 405-414
69. Loebstein R., Addis A., Ho E., et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrobial Agents Chemother 42 6 (1998) 1336-1339
70. Larsen H., Nielsen G.L., Schonheyder H.C., et al. Birth outcome following maternal use of fluoroquinolones. Int J Antimicrob Agents 18 3 (2001) 259-262
71. Briggs. Drugs in pregnancy and lactation. 7th edition (2005), Lippincott Williams Wilkins, Philadelphia
72. Xifaxan. Package insert. 2005.
73. Czeizel A.E., Rockenbauer M., Sorensen H.T., et al. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study. Eur J Obstet Gynecol Reprod Biol 97 2 (2001) 188-192
74. Berkovitch M., Diav-Citrin O., Greenberg R., et al. First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study. Br J Clin Pharmacol 58 3 (2004) 298-302
75. Rodriguez-Pinilla E., and Martinez-Frias M.L. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 58 1 (1998) 2-5
76. Carmichael S.L., and Shaw G.M. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 86 3 (1999) 242-244
77. Park-Wyllie L., Mazzotta P., Pastuszak A., et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62 6 (2000) 385-392
78. Gur C., Diav-Citrin O., Shechtman S., et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 18 1 (2004) 93-101
79. Armenti V.T., Moritz M.J., Cardonick E.H., et al. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs 62 16 (2002) 2361-2375
80. Beaulieu D.B., Ananthakrishnan A.N., Issa M., et al. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis 15 1 (2009) 25-28
81. Gluck P.A., and Gluck J.C. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. Curr Med Res Opin 21 7 (2005) 1075-1084
82. Norjavaara E., and de Verdier M.G. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol 111 4 (2003) 736-742
83. Patlas N., Golomb G., Yaffe P., et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60 2 (1999) 68-73
84. Ornoy A., Wajnberg R., and Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22 4 (2006) 578-579
85. Del Campo M., Kosaki K., Bennett F.C., et al. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 60 1 (1999) 10-12
86. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 108 (2001) 776-789
87. Polifka J.E., and Friedman J.M. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 65 5 (2002) 240-261
88. de Boer N.K., Jarbandhan S.V., de Graaf P., et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 101 6 (2006) 1390-1392
89. Norgard B., Pedersen L., Fonager K., et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 17 6 (2003) 827-834
90. Alstead E.M., Ritchie J.K., Lennard-Jones J.E., et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 99 2 (1990) 443-446
91. Khan Z.H., Mayberry J.F., Spiers N., et al. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 62 4 (2000) 249-254
92. Moskovitz D.N., Bodian C., Chapman M.L., et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99 4 (2004) 656-661
93. Zlatanic J., Korelitz B.I., Rajapakse R., et al. Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease. J Clin Gastroenterol 36 4 (2003) 303-309
94. Norgard B., Pedersen L., Christensen L.A., et al. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 102 7 (2007) 1406-1413
95. Goldstein L.H., Dolinsky G., Greenberg R., et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 79 10 (2007) 696-701
96. Moretti M.E., Verjee Z., Ito S., et al. Breast-feeding during maternal use of azathioprine. Ann Pharmacother 40 12 (2006) 2269-2272
97. Gardiner S.J., Gearry R.B., Roberts R.L., et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 62 4 (2006) 453-456
98. Sau A., Clarke S., Bass J., et al. Azathioprine and breastfeeding: is it safe?. BJOG 114 4 (2007) 498-501
99. Christensen L.A., Dahlerup J.F., Nielsen M.J., et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 28 10 (2008) 1209-1213
100. Bar Oz B., Hackman R., Einarson T., et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 71 8 (2001) 1051-1055
101. Nagy S., Bush M.C., Berkowitz R., et al. Pregnancy outcome in liver transplant recipients. Obstet Gynecol 102 1 (2003) 121-128
102. Angelberger S., Reinisch W., and Dejaco C. Prevention of abortion by ciclosporin treatment of fulminant ulcerative colitis during pregnancy. Gut 55 9 (2006) 1364-1365
103. Bertschinger P., Himmelmann A., Risti B., et al. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol 90 2 (1995) 330
104. Reindl W., Schmid R.M., and Huber W. Cyclosporin A treatment of steroid-refractory ulcerative colitis during pregnancy: report of two cases. Gut 56 7 (2007) 1019
105. Jain A., Venkataramanan R., Fung J.J., et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 64 4 (1997) 559-565
106. Kainz A., Harabacz I., Cowlrick I.S., et al. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int 13 Suppl 1 (2000) S299-S300
107. Jain A.B., Reyes J., Marcos A., et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation 76 5 (2003) 827-832
108. Baumgart D.C., Sturm A., Wiedenmann B., et al. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 54 12 (2005) 1822-1823
109. Ehrenpreis E.D., Kane S.V., Cohen L.B., et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117 6 (1999) 1271-1277
110. Celgene-Corporation. Thalomid. Product Information. 2000.
111. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 9317 (2002) 1541-1549
112. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 23 (2005) 2462-2476
113. Simister N.E. Placental transport of immunoglobulin G. Vaccine 21 24 (2003) 3365-3369
114. Lichtenstein G., Cohen R.D., Feagan B.G., et al. Safety of infliximab in Crohn's disease: data from the 5000- patient TREAT Registry. [abstract]. Gastroenterology 126 Suppl 4 (2004) A54
115. Katz J.A., Antoni C., Keenan G.F., et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 99 12 (2004) 2385-2392
116. Mahadevan U., Kane S., Sandborn W.J., et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 21 6 (2005) 733-738
117. Schnitzler F., Fidder H., Ferrante M., et al. Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease. [abstract]. Gastroenterology 132 4 Suppl 2 (2007) 958
118. Vasiliauskas E.A., Church J.A., Silverman N., et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 4 10 (2006) 1255-1258
119. Mahadevan U., Terdiman J., Church J., et al. Infliximab levels in infants born to women with inflammatory bowel disease. [abstract]. Gastroenterol 132 4 Suppl 2 (2007) A144
120. Kane S., Ford J., Cohen R., et al. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 43 7 (2009) 613-616
121. Peltier M., James D., Ford J., et al. Infliximab levels in breast-milk of a nursing Crohn's patient. [abstract]. Am J Gastroenterol 96 9 Suppl 1 (2001) P258
122. Mahadevan U.K.S., Church J., Vasiliauskas E., et al. The effect of maternal peripartum infliximab use on neonatal immune response. [abstract]. Gastroenterology 134 4 suppl 1 (2008) A69
123. Kaine J.L., Kivitz A.J., Birbara C., et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 34 2 (2007) 272-279
124. Sands B.E., Cuffari C., Katz J., et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 10 5 (2004) 677-692
125. Hanaver S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333 [quiz 591]
126. Coburn L.A., Wise P.E., and Schwartz D.A. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 51 11 (2006) 2045-2047
127. Mishkin D.S., Van Deinse W., Becker J.M., et al. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 12 8 (2006) 827-828
128. Vesga L., Terdiman J.P., and Mahadevan U. Adalimumab use in pregnancy. Gut 54 6 (2005) 890
129. Nesbitt A.B.D., Stephens S., and Foulkes R. Placental transfer and accumulation in milk of the anti-TNF antibody TN3 in rats: immunoglobulin G1 versus PEGylated Fab'. [abstract]. Am J Gastroenterol 101 (2006) 1119
130. Mahadevan U.S.C., and Abreu M. Certolizumab use in pregnancy: low levels detected in cord blood. [abstract]. Gastroenterology 136 5 (2009) 960
131. Oussalah A., Bigard M.A., and Peyrin-Biroulet L. Certolizumab use in pregnancy. Gut 58 4 (2009) 608
132. Olsen S.F., Sorensen J.D., Secher N.J., et al. Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet 339 8800 (1992) 1003-1007
133. Rossi E., and Costa M. Fish oil derivatives as a prophylaxis of recurrent miscarriage associated with antiphospholipid antibodies (APL): a pilot study. Lupus 2 5 (1993) 319-323
134. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134 7 (2008) 1861-1868